secwatch.observer — SEC 8-K summary
======================================

Issuer:     AtriCure, Inc. (ATRC)
CIK:        0001323885
Form:       8-K
Filed at:   2022-02-15T23:59:59+00:00
Accession:  0001323885-22-000008
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AtriCure Q4 revenue $73.2M (+26.8% YoY); guides FY22 rev $315-330M
------------------------------------------------------------------

- Q4 2021 revenue $73.2M (+26.8% YoY); U.S. $61.2M (+29.1%), Intl $12.0M (+16.3%).
- FY2021 revenue $274.3M (+32.8%); GAAP net income $1.11/shr; adj loss per share $1.16.
- FY2021 includes $184.8M credit for contingent consideration change and $82.3M IPR&D impairment.
- FY2022 revenue guidance $315-330M (15-20% growth); adj EBITDA loss $2-4M; adj loss/shr $1.07-1.12.
- Milestones: Hybrid Therapy FDA approval, ENCOMPASS 510(k), Cryo Nerve Block expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1323885/000132388522000008/0001323885-22-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1323885/000132388522000008/atrc-20220215.htm
  HTML page:      https://secwatch.observer/filing/0001323885-22-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer